GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Operating Margin %

Acura Pharmaceuticals (Acura Pharmaceuticals) Operating Margin % : -658.33% (As of Dec. 2021)


View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Acura Pharmaceuticals's Operating Income for the three months ended in Dec. 2021 was $-0.24 Mil. Acura Pharmaceuticals's Revenue for the three months ended in Dec. 2021 was $0.04 Mil. Therefore, Acura Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2021 was -658.33%.

The historical rank and industry rank for Acura Pharmaceuticals's Operating Margin % or its related term are showing as below:


ACUR's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.34
* Ranked among companies with meaningful Operating Margin % only.

Acura Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Acura Pharmaceuticals's Operating Income for the three months ended in Dec. 2021 was $-0.24 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2021 was $-1.21 Mil.


Acura Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Acura Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acura Pharmaceuticals Operating Margin % Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -176.16 -954.88 -27.29 -21.23 -77.67

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.25 -22.67 -48.94 -196.67 -658.33

Competitive Comparison of Acura Pharmaceuticals's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acura Pharmaceuticals's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Operating Margin % falls into.



Acura Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Acura Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-1.214 / 1.563
=-77.67 %

Acura Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2021 ) / Revenue (Q: Dec. 2021 )
=-0.237 / 0.036
=-658.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acura Pharmaceuticals  (OTCPK:ACUR) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Acura Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.
Executives
Bruce F Wesson director 1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly director C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross director 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh officer: VP, Corporate Development
Immanuel Thangaraj director 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser officer: VP, Treasurer & Controller C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones officer: President & CEO C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko officer: VP Pharmaceutical Sciences APT C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens officer: Senior VP & CFO C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc 10 percent owner 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc 10 percent owner C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte 10 percent owner 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P 10 percent owner 610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc 10 percent owner 680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp 10 percent owner 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020

Acura Pharmaceuticals (Acura Pharmaceuticals) Headlines